{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:27:17Z","timestamp":1758479237563},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2009,9,11]],"date-time":"2009-09-11T00:00:00Z","timestamp":1252627200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1000503","type":"journal-article","created":{"date-parts":[[2009,9,10]],"date-time":"2009-09-10T21:56:12Z","timestamp":1252619772000},"page":"e1000503","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":50,"title":["Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib"],"prefix":"10.1371","volume":"5","author":[{"given":"Jasmine","family":"Foo","sequence":"first","affiliation":[]},{"given":"Mark W.","family":"Drummond","sequence":"additional","affiliation":[]},{"given":"Bayard","family":"Clarkson","sequence":"additional","affiliation":[]},{"given":"Tessa","family":"Holyoake","sequence":"additional","affiliation":[]},{"given":"Franziska","family":"Michor","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2009,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/199079a0","article-title":"A Quantitative Assay for the Number of Murine Lymphoma Cells Capable of Proliferation in Vivo.","volume":"199","author":"WR Bruce","year":"1963","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.","volume":"367","author":"T Lapidot","year":"1994","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood.V95.3.1007.003k35_1007_1013","article-title":"A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia.","volume":"95","author":"C Cobaleda","year":"2000","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells.","volume":"414","author":"T Reya","year":"2001","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/ni1080","article-title":"Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.","volume":"5","author":"KJ Hope","year":"2004","journal-title":"Nat Immunol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.tcb.2005.07.004","article-title":"Cancer stem cells: lessons from leukemia.","volume":"15","author":"JC Wang","year":"2005","journal-title":"Trends Cell Biol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia.","volume":"340","author":"CL Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.","volume":"243","author":"JD Rowley","year":"1973","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.","volume":"344","author":"BJ Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/0008-5472.CAN-06-2014","article-title":"Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.","volume":"67","author":"M Holtz","year":"2007","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response.","volume":"104","author":"J Cortes","year":"2004","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1600-0609.2004.00257.x","article-title":"Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.","volume":"72","author":"W Ghanima","year":"2004","journal-title":"Eur J Haematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20096","article-title":"Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.","volume":"76","author":"T Higashi","year":"2004","journal-title":"Am J Hematol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","article-title":"Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.","volume":"28","author":"MJ Mauro","year":"2004","journal-title":"Leuk Res"},{"key":"ref15","first-page":"979","article-title":"Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.","volume":"90","author":"S Merante","year":"2005","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia.","volume":"435","author":"F Michor","year":"2005","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.","volume":"109","author":"P Rousselot","year":"2007","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.","volume":"8","author":"JF Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood.V86.9.3314.bloodjournal8693314","article-title":"Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro.","volume":"86","author":"L Ponchio","year":"1995","journal-title":"Blood"},{"key":"ref20","first-page":"445","article-title":"Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment.","volume":"25","author":"GB Bradford","year":"1997","journal-title":"Exp Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1196\/annals.1392.005","article-title":"Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche.","volume":"1106","author":"F Arai","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrg2269","article-title":"Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation.","volume":"9","author":"KW Orford","year":"2008","journal-title":"Nat Rev Genet"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","article-title":"Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair.","volume":"135","author":"A Wilson","year":"2008","journal-title":"Cell"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nbt.1517","article-title":"Analysis of histone 2B-GFP retention reveals slowly cycling hematopoietic stem cells.","volume":"27","author":"A Foudi","year":"2009","journal-title":"Nat Biotechnol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1182\/blood.V90.11.4384","article-title":"Functional heterogeneity of human CD34(+) cells isolated in subcompartments of the G0\/G1 phase of the cell cycle.","volume":"90","author":"A Gothot","year":"1997","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood.V89.2.465","article-title":"The unexpected G0\/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood.","volume":"89","author":"N Uchida","year":"1997","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/blood.V96.13.4185","article-title":"Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S\/G(2)\/M transit and do not reenter G(0).","volume":"96","author":"H Glimm","year":"2000","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.20010916","article-title":"Changes in the proliferative activity of human hematopoietic stem cells in NOD\/SCID mice and enhancement of their transplantability after in vivo treatment with cell cycle inhibitors.","volume":"196","author":"J Cashman","year":"2002","journal-title":"J Exp Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1084\/jem.20050967","article-title":"Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates.","volume":"202","author":"E Passegue","year":"2005","journal-title":"J Exp Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.","volume":"94","author":"T Holyoake","year":"1999","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"SM Graham","year":"2002","journal-title":"Blood"},{"key":"ref32","article-title":"A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.","author":"MW Drummond","year":"2009","journal-title":"Leukemia"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.1073\/pnas.0501870102","article-title":"Drug resistance in cancer: principles of emergence and prevention.","volume":"102","author":"NL Komarova","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1634\/stemcells.2006-0136","article-title":"Successful therapy must eradicate cancer stem cells.","volume":"24","author":"D Dingli","year":"2006","journal-title":"Stem Cells"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"14931","DOI":"10.1073\/pnas.0607006103","article-title":"The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.","volume":"103","author":"F Michor","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.","volume":"12","author":"I Roeder","year":"2006","journal-title":"Nat Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.1371\/journal.pone.0000990","article-title":"Effect of cellular quiescence on the success of targeted CML therapy.","volume":"2","author":"NL Komarova","year":"2007","journal-title":"PLoS ONE"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/stemcells.2006-0638","article-title":"CML blast arises from progenitors.","volume":"25","author":"F Michor","year":"2007","journal-title":"Stem Cells"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e1000095","DOI":"10.1371\/journal.pcbi.1000095","article-title":"Dynamics and potential impact of the immune response to chronic myelogenous leukemia.","volume":"4","author":"PS Kim","year":"2008","journal-title":"PLoS Comput Biol"},{"key":"ref40","first-page":"1","article-title":"Biology of chronic myelogenous leukemia: is discordant maturation the primary defect?","volume":"25","author":"A Strife","year":"1988","journal-title":"Semin Hematol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.leu.2402444","article-title":"Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.","volume":"16","author":"TL Holyoake","year":"2002","journal-title":"Leukemia"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/1078-0432.CCR-05-0429","article-title":"Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.","volume":"12","author":"HG Jorgensen","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"ME Gorre","year":"2001","journal-title":"Science"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.","volume":"99","author":"S Branford","year":"2002","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.","volume":"102","author":"S Branford","year":"2003","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"NP Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.","volume":"100","author":"C Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-1161(89)90001-0","article-title":"A statistical model to estimate variance in long term-low dose mutation assays: testing of the model in a human lymphoblastoid mutation assay.","volume":"216","author":"AR Oller","year":"1989","journal-title":"Mutat Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.","volume":"351","author":"CH Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation.","volume":"109","author":"Y Wang","year":"2007","journal-title":"Blood"},{"key":"ref51","article-title":"Growth Factor Deprivation Combined with Prolonged Inhibition of BCR-ABL Does Not Eradicate Functional CML Stem Cells.","volume":"112","author":"AHG Hamilton","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["PLoS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T03:34:09Z","timestamp":1590118449000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1000503"}},"subtitle":[],"editor":[{"given":"Christophe","family":"Fraser","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2009,9,11]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,9,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1000503","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,11]]}}}